8-K: Bio-Techne Reports Q4 FY26 Results Amid Merck Acquisition

Bio-Techne Corporation announced its fourth quarter and full year fiscal 2026 results, highlighting a 3% organic revenue increase in Q4 and confirming its acquisition by Merck KGaA for $73 per share.

Summary

• Bio-Techne Corporation reported fourth quarter fiscal year 2026 results with organic revenue up 3% to $321.2 million, while full year organic and reported revenue remained flat at $1.2 billion.
• GAAP EPS for the fourth quarter was $0.35, an increase from $(0.11) in the prior year, and full year GAAP EPS rose to $1.16 from $0.46.
• Adjusted EPS for the fourth quarter was $0.52, a slight decrease from $0.53 in the prior year, while full year adjusted EPS increased to $1.93 from $1.92.
• The company announced it entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion.
• The Protein Sciences segment saw a 1% organic revenue increase in Q4 and a 1% increase for the full year.
• The Diagnostics and Spatial Biology segment reported an 8% organic revenue increase in Q4, but a 3% decrease in full year net sales, with organic growth of 4%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, primarily due to the acquisition by Merck KGaA, which offers a significant premium, despite mixed operational results.

Positives

• The acquisition by Merck KGaA, Darmstadt, Germany, at $73 per share offers a significant premium and a total enterprise value of approximately $11.3 billion.
• Fourth quarter organic revenue increased by 3% to $321.2 million.
• Full year GAAP EPS increased significantly to $1.16 from $0.46 in the prior year.
• Full year adjusted EPS saw a slight increase to $1.93 from $1.92.
• Adjusted operating income for the fourth quarter increased to $103.4 million from $101.3 million in the prior year.
• Adjusted operating margin improved slightly to 32.2% in Q4 from 32.0% in the prior year.
• The Diagnostics and Spatial Biology segment showed strong organic revenue growth of 8% in the fourth quarter.
• The company declared a quarterly cash dividend of $0.08 per share.

Negatives

• Full year organic and reported revenue remained flat at $1.2 billion.
• Adjusted EPS for the fourth quarter decreased slightly to $0.52 from $0.53 in the prior year.
• The Protein Sciences segment's operating margin decreased to 42.0% in Q4 from 43.6% in the prior year, primarily due to unfavorable volume and product mix.
• The Protein Sciences segment's full year operating margin decreased to 41.1% from 42.6%.
• The Diagnostics and Spatial Biology segment's full year net sales decreased by 3%.

Risks

• The integration of new businesses and leadership.
• The introduction and acceptance of new products.
• The funding and focus of research by customers.
• The impact of increased competition in the biotechnology research products market.
• General economic conditions.
• The impact of currency exchange rate fluctuations.
• The costs and results of research and product development efforts.
• Potential risks and uncertainties associated with the pending acquisition by Merck KGaA.

Future Outlook

The company is progressing towards the completion of its acquisition by Merck KGaA, Darmstadt, Germany, and anticipates that this transaction will create opportunities for its customers and employees. No specific future financial guidance is provided due to the pending acquisition.

Management Comments

• "Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research and diagnostic workflows," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne.
• "We continue to make progress toward completing Bio-Technes acquisition by Merck KGaA, Darmstadt, Germany, and look forward to the opportunities this transaction is expected to create for our customers and employees."

Industry Context

StockSavvy.ai notes that the life sciences tools and diagnostics sector is characterized by consolidation, with larger players acquiring innovative companies. Bio-Techne's acquisition by Merck KGaA aligns with this trend, suggesting a strategic move to enhance Merck's capabilities in areas like spatial biology and diagnostics.

Legal Proceedings

• The filing references 'Certain litigation charges' in its financial reconciliations, indicating ongoing or past legal matters, but provides no specific details.

Stakeholder Impact

• Shareholders: Will receive $73 per share in cash upon completion of the acquisition, representing a significant return.
• Employees: The acquisition is expected to create opportunities, though specific impacts on roles and integration are not detailed.
• Customers: The transaction is expected to create opportunities, potentially leading to enhanced product offerings and services.
• Creditors: The acquisition by a larger entity may provide increased financial stability.

Next Steps

• Complete the acquisition by Merck KGaA, Darmstadt, Germany.
• The Board of Directors will consider future cash dividends on a quarterly basis.

Key Dates

Recommendation

The pending acquisition at a significant premium ($73/share) provides a clear exit for shareholders, making a 'hold' appropriate to await deal closure. While operational performance was mixed, the acquisition value outweighs the current standalone growth trajectory. Investors should monitor the closing conditions of the Merck KGaA deal.

Keywords

Bio-Techne, Merck KGaA, Life Sciences, Diagnostics, Spatial Biology, Protein Sciences, Financial Results, Acquisition